. 2019 Nov 14;30(11):1796–1803. doi: 10.1093/annonc/mdz387

Table 3.

Response rates (ORR) according to CMS

RASwt	CMS1	P*	CMS2	P*	CMS3	P*	CMS4	P*	Chi-square P	CMS 1–4	P*	CMS 1–4 left-sided	P*	CMS 1–4 right-sided	P*
(n = 315)
FOLFIRI Cet	61%	0.54	88%	0.043	74%	0.13	76%	0.049		67%	0.049	71%	0.06	52%	0.81
FOLFIRI Bev	50%	0.54	71%	0.043	42%	0.13	55%	0.049		56%	0.049	58%	0.06	47%	0.81
Both arms	55%		78%		61%		66%		0.027	61%		65%		49%
(n = 123)
FOLFIRI Cet	40%	0.58	58%	0.46	50%	0.70	40%	0.054		39%	0.28	40%	0.38	40%	0.75
FOLFIRI Bev	67%	0.58	39%	0.46	39%	0.70	74%	0.054		50%	0.28	51%	0.38	47%	0.75
Both arms	57%		47%		44%		56%		0.71	45%		46%		44%
(n = 438)
FOLFIRI Cet	54%	0.59	81%	0.03	66%	0.11	63%	0.73		59%	0.29	63%	0.26	47%	>0.99
FOLFIRI Bev	55%	0.59	64%	0.03	42%	0.11	60%	0.73		54%	0.29	57%	0.26	47%	>0.99
Both arms	55%		71%		55%		62%		0.051	57%		60%		47%

CMS, consensus molecular subgroup; P*, two-sided Fisher’s exact test P; Cet, cetuximab; Bev, bevacizumab; RASwt, RAS wild-type.